Last reviewed · How we verify
cis-UCA solution
At a glance
| Generic name | cis-UCA solution |
|---|---|
| Sponsor | BioCis Pharma Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 2 Study With Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye (PHASE2)
- Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer (PHASE1)
- Safety, Tolerability and Pharmacokinetics of 0.5% and 2.5% Cis-UCA Eye Drops in Adult Healthy Volunteers (Phase I) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cis-UCA solution CI brief — competitive landscape report
- cis-UCA solution updates RSS · CI watch RSS
- BioCis Pharma Ltd portfolio CI